Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q13946

UPID:
PDE7A_HUMAN

ALTERNATIVE NAMES:
HCP1; TM22

ALTERNATIVE UPACC:
Q13946; A0AVH6; A8K436; A8K9G5; O15380; Q96T72

BACKGROUND:
The enzyme High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A, known as HCP1 or TM22, is integral to the degradation of cAMP, a key regulator of vital physiological processes. This enzyme's involvement in muscle signal transduction underscores its significance in muscle function and overall cellular communication.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A offers a promising avenue for the development of novel therapeutic approaches. Given its pivotal role in cAMP metabolism, targeting this enzyme could provide new strategies for treating conditions associated with aberrant cAMP signaling.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.